Tests tumor genetic profiling in adults with advanced cancer
Tests tumor gene testing in adults with advanced breast, lung, skin or sarcoma cancer.
Plain-language title generated from the registry record
Registry title: BostonGene and Exigent Genomic INsight Study
Key facts
- Where
- Albuquerque, Fort Wayne, Houston, Puyallup, Rogers, Stockton, and Tulsa, United StatesSee the 7 sites
Where in United States
- New Mexico Cancer CenterAlbuquerque, United StatesTaking people
- Fort Wayne Medical Oncology and HematologyFort Wayne, United StatesTaking people
- Oncology ConsultantsHouston, United StatesTaking people
- Northwest Medical SpecialitiesPuyallup, United StatesTaking people
- Highlands Oncology GroupRogers, United StatesTaking people
- Stockton Hematology Oncology Medical GroupStockton, United StatesTaking people
- Oklahoma Cancer Specialists and Research InstituteTulsa, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- BostonGene
- Trial code
- NCT06272864
- Record updated
- 17 February 2025
- Original description
The BEGIN Study by BostonGene and Exigent Genomic INsight evaluates the efficacy of comprehensive molecular testing in advanced cancer patients. Using the BostonGene Tumor Portrait test, the study aims to identify actionable findings, assess feasibility, and determine patient enrollment in clinical trials. Four cohorts of 100 patients each will be studied over two years, focusing on treatment decisions and patient outcomes. This study seeks to demonstrate the clinical utility of genomic testing in guiding therapy for advanced cancer patients in community settings.Read full original descriptionShow less
BostonGene and Exigent Genomic INsight (BEGIN) Study: A Prospective Study of Comprehensive Molecular Testing in Advanced Cancer Patients in the Community Setting
The BEGIN Study by BostonGene and Exigent Genomic INsight evaluates the efficacy of comprehensive molecular testing in advanced cancer patients. Using the BostonGene Tumor Portrait test, the study aims to identify actionable findings, assess feasibility, and determine patient enrollment in clinical trials. Four cohorts of 100 patients each will be studied over two years, focusing on treatment decisions and patient outcomes. This study seeks to demonstrate the clinical utility of genomic testing in guiding therapy for advanced cancer patients in community settings.
Inclusion: Patients must have a confirmed malignancy of:; Locally recurrent, unresectable, or metastatic breast cancer or; Unresectable stage III or metastatic non-small cell lung cancer or; Unresectable or metastatic melanoma or; Locally advanced or metastatic l sarcoma; Life expectancy > 3 months as per the treating physician; Willingness to provide informed consent; Living in the United States at time of enrollment; Agree to participate in genomic and molecular profiling.
Exclusion: not meeting the inclusion criteria.